Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

se of this study is to assess the efficacy and safety of lower doses of quizartinib in the treatment of patients 18-years or older with relapsed/refractory FLT3 ITD positive AML to further improve the benefit:risk assessment of quizartinib. The data will be presented by Dr. Jorge Cortes at 3:00 pm CT on Monday, December 9, in the La Nouvelle Ballroom C.

Quizartinib Can Be Safely Combined With Conventional Chemotherapy In Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Experience From The AML Pilot Trial:  This is the first presentation of quizartinib use in combination with chemotherapy in newly diagnosed older AML patients, testing the feasibility and dose which could be given sequentially following conventional chemotherapy in patients over the age of 60 years.  The data will be presented by Dr. Alan Burnett at 5:15 pm CT on Monday, December 9, in the La Nouvelle Ballroom C.

Results of Phase 1 Study of Quizartinib In Combination with Induction and Consolidation Chemotherapy in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia:  This dose escalation study is the first to report data on quizartinib in combination with standard induction and consolidation chemotherapy in patients between the ages of 18 to 60-years with newly diagnosed AML, regardless of FLT3 status. The data will be presented by Dr. Jessica Altman at 5:30 pm CT on Monday, December 9, in the La Nouvelle Ballroom C.

A Phase I Study of Quizartinib in Combination with Cytarabine and Etoposide in Relapsed/Refractory Childhood ALL and AML:  A Therapeutic Advances in Childhood Leukemia & Lymphoma Study:  This was the first clinical trial using quizartinib in children between the ages of 1 month and 21-years with relapsed/refractory AML or MLL-rearranged ALL.  The data will be presented by Dr. Todd Coope
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... Athena Signature Series: Turning Cancer ‘Off’ – featuring ... professor in the Regulatory Biology Laboratory at the Salk Institute, ... to an “off switch” for drug resistance in cancer. , ... research is making a global impact in the fight against ... host Cheryl K. Goodman, CEO of Social Global Mobile LLC, ...
(Date:11/18/2014)... (PRWEB) November 18, 2014 Array Architects ... and design expertise to the nation's hospitals and health ... served by those dedicating their careers to the advancement ... respected contributor in her respective field, Laura Silvoy has ... at the 2014 Winter Simulation Conference. , Laura ...
(Date:11/17/2014)... (PRWEB) November 17, 2014 The ... Microgram Weights " describes the challenges of becoming ... achieve accredited status for calibration weights in the ... laboratories, weight manufacturers and any scientists involved in ... of design, handling, manufacturing and calibration of weights ...
(Date:11/15/2014)... As part of an ongoing ... in its network and logistics capabilities to meet ... the complex requirements of the industry. , The ... logistics and transportation, and includes opening new QuickSTAT ... will be an emphasis on Customer Service capabilities, ...
Breaking Biology Technology:Array Healthcare Simulation Expert Slated to Speak at Winter Simulation Conference 2New White Paper on Microgram Weights Describes How to Achieve Traceable Measurement Down to 0.05 Milligrams 2QuickSTAT Announces Global Expansion Plan to Enhance Its Global Network and Cold Chain Logistics Capabilities for Life Sciences 2
... The Medical Affairs Company LLC,(TMAC(R)), the leading ... today a significant expansion of its medical,communications division. ... an increasing client demand for clinician-staffed,project-based medical information ... the size of its Medical Communications division to,better ...
... Innovative Technology for the Minimally Invasive Treatment of ... Approval PathwayEAST PROVIDENCE, R.I., Feb. 23 IlluminOss ... innovative IlluminOss(TM) Photodynamic Bone Stabilization System for orthopedic ... ISO 13485 Certificate of Registration issued by BSI ...
... BOZEN, Italy, February 23 Health Robotics ... a definitive agreement whereby Can-Med,has acquired the ... in Armenia, Georgia, Kazakhstan, Uzbekistan, Azerbaijan,Iran, Mongolia, ... first and only automated, point-of-care-distributed, and fail-safe,robotic ...
Cached Biology Technology:The Medical Affairs Company Expands Its Medical Communications Division 2IlluminOss Medical Receives ISO 13485 Certification 2Health Robotics Expands i.v.STATION(TM) Partnership With Can-Med in 10 Countries Within Central Asia 2Health Robotics Expands i.v.STATION(TM) Partnership With Can-Med in 10 Countries Within Central Asia 3
(Date:11/4/2014)... 2014) – A majority of Madagascar,s 101 species of ... serious consequences for the rainforests they call home. A ... impacts lemurs can have on rainforest tree populations, which ... have on the region,s rich biodiversity. , A large ... by lemurs. Lemurs in turn disperse the seeds ...
(Date:11/3/2014)... Center study published in this month,s ... the activity of a recently discovered communication molecule of ... has been known to limit inflammation and the current ... IL-37 inhibits the ability of the immune system to ... that underlies IL-37,s effect on the immune system now ...
(Date:11/2/2014)... World , James Dacey explores the ways in which ... their innovations from the lab into the commercial market. ... start-up companies as they move from prototype to product ... factors: physics-based inventions are usually far from market-ready when ... a lot more complicated than had been originally thought. ...
Breaking Biology News(10 mins):Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3PNAS: From HIV to cancer, IL-37 regulates immune system 2The 'valley of death' facing physics start-ups 2
... (NAS) and Institute of Medicine (IOM) today released SCIENCE, ... public a comprehensive and up-to-date picture of the current ... science classroom. Recent advances in science and medicine, ... the past 150 years, have reinforced evolution,s role as ...
... the latest American Chemical Society (ACS) News Service Weekly PressPac ... Engineering News.,Please credit the individual journal or the American Chemical ... IS FOR IMMEDIATE USE EXCEPT ARTICLE #5, which is embargoed ... ARTICLE #1 FOR IMMEDIATE RELEASE ...
... researchers have uncovered a critical difference between flu viruses that ... monitor the evolution of avian flu strains and aid in ... The researchers found that a virus,s ability to infect humans ... of receptor on the surface of human respiratory cells. ...
Cached Biology News:Scientific evidence supporting evolution continues to grow 2Scientific evidence supporting evolution continues to grow 3American Chemical Society's weekly PressPac -- Jan. 2, 2008 2American Chemical Society's weekly PressPac -- Jan. 2, 2008 3American Chemical Society's weekly PressPac -- Jan. 2, 2008 4American Chemical Society's weekly PressPac -- Jan. 2, 2008 5American Chemical Society's weekly PressPac -- Jan. 2, 2008 6American Chemical Society's weekly PressPac -- Jan. 2, 2008 7American Chemical Society's weekly PressPac -- Jan. 2, 2008 8American Chemical Society's weekly PressPac -- Jan. 2, 2008 9MIT finds key to avian flu in humans 2MIT finds key to avian flu in humans 3
PI/RNase Staining Buffer Solution , 100 ml Consult technical datasheet for details....
Selenoprotein P Purified Anti-Mouse clone 35, Isotype Mouse IgG 2b , 50 µg Consult technical datasheet for details....
Anti-Mouse Reticular Fibroblast, Purified (Clone ER-TR7) (rat IgG2a)...
...
Biology Products: